Quite unexpectedly, it was shown that adjuvant treatment with bevacizumab, an anti-VEGF monoclonal antibody, after resection of high-risk melanoma significantly improves disease-free interval, rather than overall survival (66). Here, VEGFA is linked to melanoma.